These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 37629047

  • 21. [Soluble guanylate cyclase: restoration of the NO-sGC-cGMP signaling pathway activity. A new opportunity in the treatment of heart failure].
    Belenkov YN, Kozhevnikova MV.
    Kardiologiia; 2023 May 31; 63(5):68-76. PubMed ID: 37307211
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction.
    Konstantinou DM, Chatzizisis YS, Giannoglou GD.
    Pharmacol Ther; 2013 Nov 31; 140(2):156-66. PubMed ID: 23792088
    [Abstract] [Full Text] [Related]

  • 24. Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
    Correale M, Pelaggi G, Catanoso MC, Miccichè S, Teresi L, Bonanno S, Bellocchi P, Poleggi C, Capasso R, Barile M, Visco V, Carluccio E, Nodari S, Ciccarelli M, Dattilo G.
    Heart Fail Rev; 2024 Sep 31; 29(5):1135-1143. PubMed ID: 39044114
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong J, Anavekar N, Anker SD, Arango JL, Arenas JL, Atar D, Ben-Gal T, Boytsov SA, Chen CH, Chopra VK, Cleland J, Comin-Colet J, Duengen HD, Echeverría Correa LE, Filippatos G, Flammer AJ, Galinier M, Godoy A, Goncalvesova E, Janssens S, Katova T, Køber L, Lelonek M, Linssen G, Lund LH, O'Meara E, Merkely B, Milicic D, Oh BH, Perrone SV, Ranjith N, Saito Y, Saraiva JF, Shah S, Seferovic PM, Senni M, Sibulo AS, Sim D, Sweitzer NK, Taurio J, Vinereanu D, Vrtovec B, Widimský J, Yilmaz MB, Zhou J, Zweiker R, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, McMurray JJV.
    Circ Heart Fail; 2018 Jul 31; 11(7):e004962. PubMed ID: 29980595
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.
    Sahana U, Wehland M, Simonsen U, Schulz H, Grimm D.
    Int J Mol Sci; 2023 Jul 23; 24(14):. PubMed ID: 37511587
    [Abstract] [Full Text] [Related]

  • 30. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS, Tolppanen H.
    Drugs; 2021 Sep 23; 81(14):1599-1604. PubMed ID: 34478114
    [Abstract] [Full Text] [Related]

  • 31. Phosphodiesterase 2 inhibition preferentially promotes NO/guanylyl cyclase/cGMP signaling to reverse the development of heart failure.
    Baliga RS, Preedy MEJ, Dukinfield MS, Chu SM, Aubdool AA, Bubb KJ, Moyes AJ, Tones MA, Hobbs AJ.
    Proc Natl Acad Sci U S A; 2018 Jul 31; 115(31):E7428-E7437. PubMed ID: 30012589
    [Abstract] [Full Text] [Related]

  • 32. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis.
    O'Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Grzeslo A, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk LM, Moe GW, Swiggum E, Toma M, Virani SA, Zieroth S, De S, Matteau S, Parent MC, Asgar AW, Cohen G, Fine N, Davis M, Verma S, Cherney D, Abrams H, Al-Hesayen A, Cohen-Solal A, D'Astous M, Delgado DH, Desplantie O, Estrella-Holder E, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Lee D, Masoudi FA, McKelvie RS, Rajda M, Ross HJ, Sussex B.
    Can J Cardiol; 2020 Feb 31; 36(2):159-169. PubMed ID: 32036861
    [Abstract] [Full Text] [Related]

  • 33. Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Escobar C, Luis-Bonilla J, Crespo-Leiro MG, Esteban-Fernández A, Farré N, Garcia A, Nuñez J.
    Expert Opin Pharmacother; 2022 Oct 31; 23(14):1589-1599. PubMed ID: 35995759
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K, Sakata Y, Shimokawa H.
    Adv Exp Med Biol; 2018 Oct 31; 1067():17-30. PubMed ID: 29542073
    [Abstract] [Full Text] [Related]

  • 38. Cyclic GMP and PKG Signaling in Heart Failure.
    Numata G, Takimoto E.
    Front Pharmacol; 2022 Oct 31; 13():792798. PubMed ID: 35479330
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.